# F-MISO (JBS-003)

Source: https://onco.cc/drugs/jbs-003/  
OnCo record `jbs-003` (Imaging agent). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

F-MISO (JBS-003) is an experimental radiopharmaceutical PET imaging agent from Juniper Biosciences, in phase 3 trials for HPV-positive oropharyngeal cancer and HPV-positive head and neck cancer.

## Summary

F-MISO (JBS-003) (JBS-003, F-MISO, 18F-FMISO) is a radiopharmaceutical PET imaging agent (diagnostic) from Juniper Biosciences, with Memorial Sloan Kettering Cancer Center as partner. A fluorine-18 PET tracer that becomes trapped in oxygen-starved tumour cells; FMISO PET is used to pick out HPV-positive throat cancer patients whose tumours are not hypoxic and who may safely receive lower-dose radiation. Its furthest stage is phase 3, for HPV-positive oropharyngeal cancer and HPV-positive head and neck cancer. ClinicalTrials.gov registers it in 3 studies linked below. FDA Breakthrough Therapy designation reported by MSK (page updated September 2026). Phase 3 NCT06563479 recruiting, sponsored by Memorial Sloan Kettering. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Imaging agent
- Status: phase-3
- Last checked: 2026-11-03
- Also known as: JBS-003; F-MISO; 18F-FMISO; [18F]fluoromisonidazole; fluorine-18 fluoromisonidazole
- Tags: pipeline; ctgov-ingest
- Code: JBS-003
- Modality: Radiopharmaceutical PET imaging agent (diagnostic)
- Mechanism: A fluorine-18 PET tracer that becomes trapped in oxygen-starved tumour cells; FMISO PET is used to pick out HPV-positive throat cancer patients whose tumours are not hypoxic and who may safely receive lower-dose radiation.

## Sources

- Juniper Biosciences: web.archive.org: https://web.archive.org/web/20260713121640/https://juniperbiosci.com/pipeline/
- Juniper Biosciences: web.archive.org: https://web.archive.org/web/20260713121640/https://juniperbiosci.com/pipeline/
- Juniper Biosciences: mskcc.org: https://www.mskcc.org/news/low-dose-radiation-possible-game-changer-treating-hpv-positive-head-and-neck
- Juniper Biosciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06563479
- ClinicalTrials.gov: trials of JBS-003: https://clinicaltrials.gov/search?intr=JBS-003

## Connected records

- cancers: [HPV-positive oropharyngeal cancer](https://onco.cc/cancers/hpv-positive-oropharyngeal-cancer/), [Oropharyngeal cancer (tonsil and base of tongue)](https://onco.cc/cancers/oropharyngeal-cancer/)
- companies: [Juniper Biosciences](https://onco.cc/companies/juniper-biosciences/)
- trials: [A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer](https://onco.cc/trials/nct06563479/), [A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer](https://onco.cc/trials/nct05491512/), [A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer](https://onco.cc/trials/nct06984861/)

---
JSON: https://onco.cc/api/v1/entities/jbs-003.json